Clinical Trial Update: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM [Phase 4]

View source ↗

Summary

Phase 4 trial updating the durability of a triple combination therapy (exenatide, pioglitazone, and metformin) versus conventional therapy in new-onset type 2 d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• PIOGLITAZONE (Pioglitazone)
• metformin (metformin)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2024-09-05